Clinical trial · Interventional
Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block
Comparing the Analgesic Effect of Two Different Doses of Dexmedetomidine Added to Bupivacaine in Ultrasound-guided Transversus Abdominis Plane Block in Patients Undergoing Lower Abdominal Cancer Surgeries; A Randomized Clinical Trial
NCT06624319CI-TRIAL-00081277Dexmed/tapnot yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to bupivacaine in U.S guided TAP block for preemptive analgesia In patients undergoing lower abdominal cancer surgeries.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Post Operative Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexmedetomidine as adjuvent to bupvacaine in tap block | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- tap block with 0.5 μg/kg dexmedetomidine
- description
- will receive pre-emptive ultrasound-guided tap block with 0.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.
- interventionNames
- Drug: Dexmedetomidine as adjuvent to bupvacaine in tap block
- type
- ACTIVE_COMPARATOR
- label
- tap block with 1.5 μg/kg dexmedetomidine
- description
- will receive pre-emptive ultrasound-guided tap block with 1.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.
- interventionNames
- Drug: Dexmedetomidine as adjuvent to bupvacaine in tap block
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * age from 18 to 65 years old * lower abdominal cancer surgery Exclusion Criteria: * patient refusal * the local anesthetic allergy * coagulopathy * local infection at the procedure site * psychic patients * patient on chronic opioid use
References
Publications (0)
Data not yet available
No reference posted for this study.